ABOUT VASORX

A cutting edge therapeutic for modern RNAi medicine

VasoRx is leading the translation of innovative LNP technologies for the spexcific delivery of RNAs to the vasculature to treatment of various diseases. With the first approved RNAi therapeutic in the U.S., the field of RNA medicines is rapidly expanding. Delivery of these new medicines has been a major challenge, and most of the RNA pipeline therapies utilize nanoparticle technology that targets the liver. Hence, many of the products in the pipeline are targeting liver diseases.

VasoRx utilizes novel polymeric nanoparticles that preferentially target the vasculature (i.e. endothelium), dramatically expanding the opportunities for developing RNA therapies for diseases of the cardiovascular system as well as oncology.

VasoRx is a RNA medicine company focused on developing cardiovascular RNA silencing therapies that target vascular remodeling, chronic inflammation and fibrosis (scar) formation. We have discovered and patented the molecular pathway that controls endothelial-to-mesenchymal transition that drives vascular maladaptation, inflammation and remodeling that underlies progressive pulmonary hypertension, but also disease like atherosclerosis formation, like in ischemic heart disease.

Through our first-in-class nanoparticle therapeutics, we aim to restore vascular function, reduce maladaptation, chronic inflammation and and scar formation in cardiovascular disease, like pulmonary hypertension and atherosclerosis. Our solutions lead to improved pulmonary and vascular function and reduced harmful consequences of vascular inflammation - (such as progressive decrease of oxygen exchange), resulting in increased oxygenation, and hence patient quality of life.

OUR MISSION

Mitigating Chronic Vascular Remodeling and Inflammation in Pulmonary Hypertension